tiprankstipranks
Trending News
More News >

Aquestive Therapeutics price target lowered to $7 from $8 at Raymond James

Raymond James lowered the firm’s price target on Aquestive Therapeutics (AQST) to $7 from $8 and keeps an Outperform rating on the shares. Aquestive’s Q4 results slightly missed expectations, but the focus remains Anaphylm progress on track to be filed soon, and Aquestive is preparing for launch in the first quarter of 2026, the analyst tells investors in a research note.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1